Sanofi-GSK Vaccine Offers 100% Protection Against Severe COVID-19, In Discussions For Regulatory Authorization
Trials showed that two doses of the Sanofi-GSK vaccine generated 100 per cent efficacy against severe COVID-19 disease and hospitalizations in seronegative populations.




